<DOC>
	<DOCNO>NCT00859898</DOCNO>
	<brief_summary>The primary purpose study compare change baseline hemoglobin A1C achieve dapagliflozin 10 mg combination metformin XR compare metformin XR monotherapy compare Dapagliflozin monotherapy , 24 week oral administration double-blind treatment . The safety treatment dapagliflozin also assess study</brief_summary>
	<brief_title>Study Dapagliflozin Combination With Metformin XR Initiate Treatment Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Treatment naive male female , &gt; = 18 year old &lt; = 77 year old , type 2 diabetes mellitus Subjects must central laboratory prerandomization hemoglobin A1C &gt; = 7.5 &lt; = 12.0 % Cpeptide &gt; = 1.0 ng/mL ( 0.34 nmol/L ) Body Mass Index &lt; = 45 kg/m2 Must able perform self monitor blood glucose aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 3X*upper limit normal ( ULN ) Serum Total bilirubin &gt; 2 mg/dL ( 34.2 µmol/L ) Creatinine kinase &gt; 3*ULN Serum creatinine &gt; = 1.50 mg/dL ( 133 µmol/L ) male subject , &gt; = 1.40 mg/dL ( 124 µmol/L ) female subject Calcium value outside central laboratory normal reference range Currently unstable serious cardiovascular , renal , hepatic , hematological , oncological , endocrine , psychiatric , rheumatic disease Urine albumin : creatinine ratio ( UACR ) &gt; 1800 mg/g ( 203.4 mg/mmol Cr ) Severe uncontrolled hypertension define systolic blood pressure ( SBP ) &gt; =180 mmHg and/or diastolic blood pressure ( DBP ) &gt; =110 mmHg Hemoglobin &gt; =11.0 g/dL ( 110 g/L ) men ; hemoglobin &gt; =10.0 g/dL ( 100 g/L ) woman Positive hepatitis B surface antigen Positive antihepatitis C virus antibody History diabetes insipidus History diabetic ketoacidosis hyperosmolar nonketotic coma Symptoms poorly control diabetes would preclude participation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Metformin</keyword>
	<keyword>Dapagliflozin</keyword>
	<keyword>Hypoglycemic Agents</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Physiological Effects Drugs</keyword>
</DOC>